New scan could spot kidney damage from diabetes earlier

NCT ID NCT05241522

Completed Diagnosis Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This early-phase trial tested a radioactive tracer called Tc-99m-Tilmanocept to see if it can help doctors detect diabetic kidney disease using SPECT/CT scans. The study involved 57 adults with suspected diabetic kidney disease. The goal was to measure how the tracer behaves in the kidneys and whether it can tell diabetic kidney damage apart from other causes. This is not a treatment but a step toward better diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tc-99m-Tilmanocept (a radioactive tracer used for imaging)
What this could lead to: If successful, this imaging method could help doctors diagnose diabetic kidney disease earlier and more accurately, potentially leading to better treatment decisions.
What could go wrong: This is a very early phase 1 study focused on safety and imaging, not treatment. It may not lead to a reliable diagnostic test, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease hypertensive nephropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC KIDNEY DISEASE

Contacts and locations

Locations

UC San Diego Medical Center

San Diego, California, 92103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.